摘要:
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.
摘要:
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.
摘要:
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.
摘要:
Compounds of formula I: modulate the activity of γ-secretase, and hence find use in treatment or prevention of Alzheimer's disease and related conditions.
摘要:
The present invention encompasses compounds of Formula I (I) or pharmaceutically acceptable salts thereof, wherein A is the base molecule of a propionic acid or acetic acid NSAID, or a derivative thereof, X is —CO2H, 1H-tetrazol-5-yl or 2H-tetrazol-5-yl and R1 and R2 are each independently selected from the group consisting of: C1-6alkyl and C3-6cycloalkyl, as well as pharmaceutical composition comprising said compounds and methods of using said compounds. The compounds of the present invention lower the level of Aβ42 and are therefore useful for preventing, delaying or reversing the progression of Alzheimer s Disease.
摘要:
Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's disease, multiple sclerosis, asthma, and rheumatoid arthritis.
摘要:
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.
摘要:
A readhead for illuminating a sample carrier and receiving light from the sample carrier, including a housing for receiving a sample carrier, an array of light sources mounted within the housing in a fixed position relative to the sample carrier, and including first and second light-emitting diodes for emitting substantially monochromatic light of a two different wavelengths, a light guide mounted in the housing between the light-emitting diodes and the sample carrier, and a light detector coupled to receive light from the sample carrier. The readhead also includes a light source for directing excitation light of a predetermined wavelength to the sample carrier, and a light filter positioned between the sample carrier and the light detector and adapted to prevent passage therethrough of the excitation light. The readhead allows both fluorescence spectroscopy and reflectance spectroscopy to be conducted on the sample carrier.
摘要:
The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders—such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to α2δ-1 subunit of Ca channels.
摘要:
A readhead for a photometric diagnostic instrument includes a housing adapted for incorporation within the photometric diagnostic instrument, and an elongated sample table operatively engaged with the housing. The sample table is configured to support elongated reagent sample media of the type having a plurality of test areas disposed in spaced relation thereon, each of the test areas being configured to react with a sample and to change color according to an amount of a constituent or property in the sample. A light source is provided to illuminate the sample table. An imager having an elongated field of view is coupled to the housing, the elongated field of view including at least a portion of the sample table. A scanning mechanism is configured to move the field of view relative to the sample table.